DWTX Stock Overview
A development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Dogwood Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.55 |
| 52 Week High | US$23.50 |
| 52 Week Low | US$1.62 |
| Beta | 1.57 |
| 11 Month Change | -38.26% |
| 3 Month Change | -51.54% |
| 1 Year Change | -83.22% |
| 33 Year Change | -97.94% |
| 5 Year Change | n/a |
| Change since IPO | -99.39% |
Recent News & Updates
Recent updates
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Aug 24
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?
May 11Virios Therapeutics slides 11% postmarket on proposed stock offering
Sep 19Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07
Aug 11Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jun 25Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Mar 09Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?
Nov 02Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jul 19Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study
Jun 04Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans
Mar 31Virios Therapeutics gains 10% on research deal in irritable bowel syndrome
Feb 01Virios Therapeutics prices IPO at $10
Dec 17Shareholder Returns
| DWTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.1% | 2.4% | 2.2% |
| 1Y | -83.2% | 16.2% | 31.7% |
Return vs Industry: DWTX underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: DWTX underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| DWTX volatility | |
|---|---|
| DWTX Average Weekly Movement | 25.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DWTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DWTX's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 4 | Greg Duncan | www.dwtx.com |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
Dogwood Therapeutics, Inc. Fundamentals Summary
| DWTX fundamental statistics | |
|---|---|
| Market cap | US$3.61m |
| Earnings (TTM) | -US$5.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs DWTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DWTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.73m |
| Earnings | -US$5.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DWTX perform over the long term?
See historical performance and comparison